Abdominal myomectomy is the preferred treatment in women with large or numerous intramural myomas, especially in the setting of infertility, recurrent pregnancy loss, and preservation of future fertility. However, postoperative adhesions are distressingly common following this procedure, resulting in significant potential morbidity. Fortunately, a number of products can reduce their occurrence. Proper surgical techniques and a thorough knowledge of these products are invaluable in helping reduce the incidence of adhesions.

The association between adhesions and diminished fertility is well-established, particularly when peritubal involvement is present (FIGURES 1–3). Abdominopelvic adhesions also contribute to significant chronic pelvic pain, bowel obstruction, and technical difficulty in subsequent surgical or assisted-reproduction procedures. Unfortunately, most attempts at adhesiolysis meet with less than complete success, since adhesions recur in 55% to 100% of patients (FIGURE 4). Thus, preventing adhesions in the first place would seem to be key to successful outcomes in abdominal myomectomy.

This article reviews the evidence on various approaches and products. While the number of studies examining each adjuvant in the setting of abdominal myomectomy is limited, the overall evidence supports the safety and efficacy of both liquid and barrier adjuvants.

Adhesions present a significant clinical dilemma after abdominal myomectomy, occurring in 50% to 90% of patients. In 1 prospective series of women undergoing second-look...
laparoscopy (SLL) after myomectomy, adnexal adhesions were noted in 94% of patients with posterior uterine incisions and in 56% of patients with only anterior or fundal incisions; adhesions between the uterus and omentum or bowel occurred in 88% of all patients.3

In another study of early SLL following abdominal myomectomy, 83% of patients had adhesions between the surgical site and the bowel or omentum, and 65% had adhesions involving the adnexae.2 Removal of large, bulky fibroids (with uterine mass exceeding 13 weeks’ gestational size) resulted in higher adhesion scores than did small myomas. Again, the incidence and severity of adhesions also correlated with location of the uterine incision: Adnexal adhesions were more common after posterior uterine incisions (76%) than after anterior or fundal entries (45%).2

**Causes of pelvic adhesions**

A dhesion prevention requires an understanding of risk factors and maneuvers that increase the likelihood of injury (see “Pathophysiology of adhesion formation” on page 27). A number of causes have been proposed, most of them centering on tissue and peritoneal trauma (TABLE 1).

**Injury** can arise from excessive or rough manipulation of tissue and peritoneal surfaces or from common effects such as cutting, abrasion, and denudation (FIGURE 5). Tissue desiccation or manual blotting may lead to peritoneal desquamation and fibrin deposition.

**Exposure of surfaces to intraperitoneal blood** in the setting of tissue hypoxia—virtually unavoidable during abdominal myomectomy—disrupts normal fibrinolytic activity, resulting in stimulation of angiogenesis.4

**Introduction of reactive foreign bodies** such as talc powder, residual suture material, and even lint from laparotomy pads can favor adhesion formation. These serve as substrates or niduses of fibrin deposition.
Techniques that may help prevent adhesions

Based on findings from studies of second-look procedures, most physicians advocate avoiding posterior uterine incisions, as well as minimizing the number and extent of incisions, to help reduce the likelihood of adhesion formation. Further, many Ob/Gyns favor removing myomas through as few uterine incisions as possible. We select anterior hysterotomy sites that enable removal of multiple fibroids, avoiding posterior incisions and the uterotubal junction whenever possible.

Interestingly, reapproximation of peritoneal defects after reproductive surgery (and, probably, myomectomy) does not appear to help prevent adhesions. Tulandi and colleagues examined the clinical and SLL outcomes of peritoneal closure in patients undergoing Pfannenstiel incisions with or without peritoneal closure at the end of the procedure. There was no difference in postoperative complications or wound heal-

### Table 2: Pharmacologic agents studied for adhesion prevention in reproductive surgery

<table>
<thead>
<tr>
<th>AGENT</th>
<th>THEORETICAL ACTION</th>
<th>EXAMPLES</th>
<th>MODE OF USE/ APPLICATION</th>
<th>RISKS/PROBLEMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotics</td>
<td>Prevent infection or inflammation</td>
<td>Cephalosporins</td>
<td>Intrapertitoneal irrigation with antibiotic fluid</td>
<td>Theoretical reaction to antibiotic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tetracyclines</td>
<td>Hydrotubation fluid with antibiotic</td>
<td></td>
</tr>
<tr>
<td>Anticoagulants</td>
<td>Clot prevention</td>
<td>Heparin</td>
<td>In conjunction with Interceed</td>
<td>Risk of postoperative bleeding</td>
</tr>
<tr>
<td>Anti-inflammatory agents</td>
<td>Decrease permeability and histamine release</td>
<td>Nonsteroidal anti-inflammatories</td>
<td>Awaiting further investigation</td>
<td>Theoretical reaction to agent</td>
</tr>
<tr>
<td>Crystallloid solutions</td>
<td>Hydroflotation effect, decrease surface contact between pelvic organs</td>
<td>Normal saline, Ringer's lactate</td>
<td>Intra-abdominal instillation</td>
<td>Possible volume overload from intravascular absorption</td>
</tr>
<tr>
<td>Fibrinolytic agents</td>
<td>Fibrinolysis</td>
<td>Streptokinase, Trypsin, Fibrinolysin</td>
<td>Awaiting further investigation</td>
<td>Theoretical risk of postoperative bleeding</td>
</tr>
<tr>
<td>Steroids</td>
<td>Decrease inflammatory response</td>
<td>Dexamethasone</td>
<td>Systemic and/or intraperitoneal</td>
<td>Possible suppression of hypothalamic-pituitary axis</td>
</tr>
<tr>
<td>Polysaccharide polymer</td>
<td>&quot;Siliconizing&quot; effect to coat raw surfaces</td>
<td>Dextran 70 (Hyskon)</td>
<td>200 mL placed in posterior cul-de-sac or coating surgical site surfaces</td>
<td>Abdominal bloating, anaphylaxis, pleural effusion, liver function abnormalities, wound separation, rare diffuse intravascular coagulation</td>
</tr>
<tr>
<td>Other fluid and barrier agents*</td>
<td>Peritoneal surface separation Hydroflotation</td>
<td>Absorbable and nonabsorbable barriers (see Table 3)</td>
<td>See Table 3</td>
<td>See Table 3</td>
</tr>
</tbody>
</table>

*Adjuvants studied in the setting of abdominal myomectomy
Principles of microsurgery have been adopted by reproductive surgeons to minimize the likelihood of adhesions after myomectomy and gynecologic surgery in general. The basic techniques reflect respect for tissue integrity:
- Gentle handling of tissue, with minimal manipulation of all peritoneal surfaces.
- Meticulous hemostasis. Examine all myomectomy sites to ensure adequate hemostasis prior to closure.
- Continuous irrigation to prevent tissue desiccation. We favor continuous saline irrigation throughout the procedure. We also use only moistened laparotomy sponges and pads, and avoid applying dry gauze to any tissue surface.
- Avoidance of foreign-body introduction. We use only talc-free gloves and remove all residual suture fragments and tissue debris before closure. We also perform copious saline suction-irrigation at the end of the procedure to remove as much residue as possible.
- Use of fine, nonreactive suture. We favor fine, resorbable sutures that incite as little tissue reactivity as possible. For closure of large myomectomy defects, we use braided multifilaments such as Vicryl (polyglactine 910) (Ethicon, Somerville, NJ) or Dexon (polyglycolic acid) (Davis and Geck, Danbury, Conn) for strength and ease of handling. These sutures are absorbed through simple hydrolysis and stimulate less tissue reactivity than do chromic or catgut sutures.

The idea is appealing, but a randomized, blinded comparison of “good” and “bad” microsurgical technique is unlikely, since no one would wish to perform “bad” technique.

---

### Evidence for Adhesion Reduction

<table>
<thead>
<tr>
<th>Method</th>
<th>Status</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrotubation with antibiotic solution</td>
<td>Some evidence</td>
<td>May be of benefit after tubal surgery</td>
</tr>
<tr>
<td>Animal studies suggest increased adhesion formation</td>
<td>Unproven</td>
<td>Rapid absorption (24-48 h) makes adhesion benefit unlikely</td>
</tr>
<tr>
<td>Studies with conflicting results after reproductive surgery</td>
<td>Controversial</td>
<td>Studies unlikely to be of significant benefit</td>
</tr>
<tr>
<td>Lacks FDA approval for adhesion prevention; now rarely used</td>
<td>Unproven</td>
<td></td>
</tr>
</tbody>
</table>

See Table 3

With barrier adjuvants, optimal benefit is obtained when the physician can predict potential sites of adhesions.

### Wide Range of Prevention Tools Has Been Studied

Many types of agents have been studied in an attempt to reduce postsurgical adhesions after gynecologic surgery. Although most offer little or no benefit (Table 2), a few have potential in myomectomy procedures.

Barriers that form mechanical separation (Table 3) theoretically physically separate...
Pathophysiology of adhesion formation

Adhesions are fibrous or fibrovascular bands that connect tissue surfaces in abnormal locations. Their development likely results from an imbalance in inflammatory mediators or fibrin degradation during peritoneal wound healing.

Peritoneal injury initiates the release of histamine and vasoactive kinins that mediate increased capillary permeability and outpouring of serosanguineous fluid. This proteinaceous exudate coagulates, depositing fibrinous bands between areas of denuded tissue.

Under normal circumstances, the fibrinolytic system is activated to lyse these bands within 72 hours. Peritoneal healing occurs when mesothelial cells migrate from the underlying mesenchyme to reepithelialize the injured site. Disequilibrium of the fibrin deposition-fibrinolysis system results in a persistent band that will eventually undergo fibroblast and vascular invasion.

REFERENCES

FIGURE 3 Cyst dissection

Adhesions can follow common surgeries such as paratubal cyst dissection.

have examined the adhesion-prevention benefit of other types of absorbable and nonabsorbable barriers.

Absorbable barriers

These are largely derivatives of organic materials. Their application to myomectomy may be limited by the requirement for absolute hemostasis at the site of application. Interceed (Gynecare, a division of Ethicon), which is derived from oxidized regenerated cellulose, is one of the first and most extensively evaluated barriers. A mesh synthetic designed to be placed over injured tissue, it is a derivative of the hemostatic agent Surgicell (Johnson & Johnson, New Brunswick, NJ), with modifications in weave and pore size.

Interceed offers ease of application: It can be cut to the size or shape necessary and requires no suturing. It forms a gelatinous protective layer within 8 hours of placement, and is degraded into monosaccharides and absorbed within 2 weeks.

The use of Interceed has been shown to reduce adhesions following adhesiolysis and ovarian surgery. In a large, multicenter,
prospective, randomized trial, it significantly decreased the incidence of adhesion reformation after adnexal adhesiolysis in infertility patients with bilateral tubal disease.\(^1\)

In a retrospective series of 38 infertility patients, including 19 patients after myomectomy (13 with the barrier, 6 without), reproductive outcomes were significantly better in the Interceed group, and adhesion development was reduced.\(^1\) Pregnancy rates in the 2 years following surgery were 78% in the Interceed group, compared with 47% in controls. In addition, among 23 patients who had second-look procedures, postoperative adhesions were noted in 38% of the Interceed group, compared with 86% in controls.\(^2\)

**Seprafilm** (hyaluronic acid-film) (*Genzyme Corp, Cambridge, Mass*) is a bioresorbable membrane derived from sodium hyaluronate and carboxymethylcellulose. It is absorbed

---

### Table 3

Fluid and barrier adjuvants studied for adhesion reduction after myomectomy

<table>
<thead>
<tr>
<th>AGENT</th>
<th>THEORETICAL ACTION</th>
<th>MODE OF USE/APPLICATION</th>
<th>PROBLEMS</th>
<th>EVIDENCE FOR ADHESION REDUCTION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ABSORBABLE (BARRIER)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxidized regenerated cellulose</td>
<td>Protective layer over surgical sites to prevent</td>
<td>Direct placement onto</td>
<td>Requires hemostasis</td>
<td>Prospective studies and meta-analysis support benefit in reproductive surgery including abdominal myomectomy</td>
</tr>
<tr>
<td>(Interceed)</td>
<td>surface contact</td>
<td>surface of uterus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyaluronate-carboxymethylcellulose</td>
<td>Protective layer over surgical sites to prevent</td>
<td>Direct placement around</td>
<td>Requires hemostasis</td>
<td>Multicenter prospective, randomized study supports benefit in reducing adhesions after abdominal myomectomy</td>
</tr>
<tr>
<td>derivative film (Seprafilm)</td>
<td>surface contact</td>
<td>entire uterine surface</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expanded polytetrafluoroethylene</td>
<td>Prevent contact between surgical surfaces</td>
<td>Patch sutured onto</td>
<td>Usually must be removed</td>
<td>Multicenter prospective studies support adhesion-preventive benefit after abdominal myomectomy</td>
</tr>
<tr>
<td>(GoreTex)</td>
<td></td>
<td>surface of uterus</td>
<td>Report of fistula formation</td>
<td></td>
</tr>
<tr>
<td>Pericardial patch</td>
<td>Prevent contact between surgical surfaces</td>
<td>Patch sutured onto</td>
<td>Early clinical use</td>
<td>Preliminary study (case series data only) shows potential benefit</td>
</tr>
<tr>
<td>(Shelhigh No-React)</td>
<td></td>
<td>surface of uterus</td>
<td>in myomectomy</td>
<td></td>
</tr>
<tr>
<td>Hyaluronic acid-coat (Sepracoat)</td>
<td>Diffuse coating on surgical sites and potential</td>
<td>100-mL to 250-mL</td>
<td>Limited data on efficacy</td>
<td>Small studies (multicenter, prospective, randomized, controlled trials) demonstrated reduced postoperative adhesions after reproductive surgery via laparotomy, including myomectomy</td>
</tr>
<tr>
<td></td>
<td>sites of contact</td>
<td>aliquots injected into</td>
<td>in abdominal myomectomy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>peritoneal cavity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyaluronate-carboxymethylcellulose</td>
<td>Diffuse coating on surgical sites and potential</td>
<td>300-mL aliquot into</td>
<td>Withdrawn from market for</td>
<td>Reduced adhesion formation in animal studies and in preliminary human studies</td>
</tr>
<tr>
<td>derivative gel (Intergel)</td>
<td>sites of contact</td>
<td>peritoneal cavity</td>
<td>reports of postoperative</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>pain, complications</td>
<td></td>
</tr>
</tbody>
</table>

---
from the peritoneal cavity within 1 week and is completely excreted within 1 month.

Its potential for adhesion prevention after abdominal myomectomy was examined by SLL in a multicenter, prospective, randomized, blinded study in which 127 women undergoing abdominal myomectomy at 19 institutions were randomized to either Seprafilm or no barrier. In the Seprafilm group, the barrier was wrapped circumferentially around the uterus, covering all uterine defects, at the time of abdominal closure. Clinical outcomes—including vital signs, adverse events (pain, fever, nausea), and abdominal wound complications—were similar in the control and Seprafilm groups.

In this study, the incidence (mean number of sites), severity, and extent (mean area) of uterine adhesions were significantly lower in the Seprafilm-treated patients. The proportion of patients undergoing anterior hysterotomies who were found to have no anterior uterine adhesions was 39% in the Seprafilm group, compared with 6% in the control group. The percentage of patients with at least 1 adnexa totally free of adhesions to the posterior uterus also was higher in the Seprafilm group—48% versus 31%.

Nonabsorbable barriers
GoreTex Surgical Membrane (W.L. Gore and Associates, Newark, Del) is an inert expanded polytetrafluoroethylene (PTFE) derivative that must be sutured in place. It is of potential utility in myomectomy because its application does not require absolute hemostasis. However, its usefulness and application are limited by the need for later removal.

In a multicenter, randomized, controlled trial exploring its adhesion-preventive properties after myomectomy, the GoreTex membrane significantly outperformed the barrier-free group.

In a separate multicenter, randomized clinical trial, the GoreTex membrane was more effective than Interceed in preventing adhesions after pelvic/tubal reconstructive surgery.

Yet another multicenter, randomized trial—this one involving 27 women undergoing abdominal myomectomy—used SLL to determine the extent of adhesions and to remove the barrier. The percentage of adhesion-free surgical sites was significantly higher in the GoreTex group: 56% compared with 7% in no-barrier controls.

The adhesion scores, determined by the extent (area of involvement), nature (filmy versus opaque), and tenacity (ease of lysis or dissection) of the adhesions, were significantly lower in the GoreTex group.

Histologic examination of the removed barriers demonstrated no tissue attachment to the PTFE. Despite these positive findings, however, both fistula formation and graft infection have been reported after placement of a GoreTex barrier.
The Shelhigh Pericardial No-React Patch (Herzog Surgical, Sacramento, Calif) is a new nonabsorbable adhesion barrier that was first described in gynecologic use by Pelosi and Pelosi in a case series of 20 patients.19 Consisting of a 12-cm-diameter patch of glutaraldehyde-treated bovine/porcine pericardium, this product has an excellent safety record as a permanent pericardial substitute in the cardiovascular literature and has been shown to resist calcification and adhesions.

In the Pelosi series, the patch was placed over the uterine fundus and secured by 4 monofilament sutures at the dome of the uterus and the parietal peritoneum.19 All patients underwent SLL at 6 weeks, and 3 patients also underwent third-look laparoscopy. None of the 20 women had adhesions between the abdominal wall and the bladder, bowel, uterus, or adnexae at SLL. However, minimal adhesions of the ovaries and tubes were found in 7 patients who had undergone posterior hysterotomy. Clinical trials are likely to follow this small pilot study.

**Absorbable fluid adjuvants**

With barrier adjuvants, optimal benefit is obtained when the physician can predict potential sites of adhesions. This is not a strict requirement with fluid barriers, which is their chief advantage. Among the agents described below, Seprocoat (Genzyme Corp) is available in the United States, while Intergel (Lifecore Biomedical, Chaska, Minn) was withdrawn from the market in March. Intergel, a 0.5% ferric hyaluronate formulation, is a sterile nonpyrogenic gel of highly purified sodium hyaluronate, which is ionically cross-linked with ferric ion and adjusted to isotonicity with sodium chloride.11 (Hyaluronic acid is a major component of body tissues and fluids such as peritoneal fluid, where it performs physically supportive and mechanically protective roles.)

Johns and colleagues20 studied Intergel in a randomized, multicenter, third-party-blinded, placebo-controlled study. Of the 265 patients who completed the study, 131 were given 300 mL of Intergel and 134 were given lactated Ringer’s solution (the placebo) at the time of their surgery, through the laparoscopic port. When SLL was performed 6 to 12 weeks after surgery, the mean number and severity of adhesions—overall and at the surgical site—were significantly lower in the Intergel group. Adhesions reformed in 91% of those in the control group, compared with 63% in the Intergel group.

In myomectomy patients, the modified American Fertility Society Score, which uses 24 potential adhesion sites, was reduced by 42% in the Intergel group—a statistically significant improvement.20

One major advantage of Intergel is that it reduces adhesion formation at sites distant from the area of application, secondary to its wide intra-abdominal circulation. However, as mentioned above, sales were voluntarily suspended due to post-market reports of tissue adherence, sterile foreign-body reaction, and late-onset pain that sometimes required surgical intervention. In some patients, persistent residual material was
noted at the time of subsequent surgery. Sepracoat (hyaluronic acid-coat) is a dilute solution of 0.4% hyaluronic acid in phosphate-buffered saline. It is bioresorbable, persists at the application site less than 24 hours, and is completely cleared in less than 5 days.

In a prospective, randomized, blinded, placebo-controlled, multicenter study in 1998, Diamond and colleagues compared Sepracoat with a pure phosphate-buffered saline solution in 227 women undergoing gynecologic procedures via laparotomy. The aim of the study was to assess the efficacy and safety of the fluid at sites without direct surgical trauma or adhesiolysis. Both solutions were warmed to room temperature and injected into the abdominal cavity before the procedure began (250 mL after skin incision). The solution was reapplied after irrigation or every 30 minutes (100 mL), and at the end of the procedure (250 mL) before closure. The maximum volume used was 1,000 mL. After application, the fluid was left 1 minute before suctioning. Patients underwent SLL 40 days later, and adhesions were identified at the initial procedure and at SLL.

In the Sepracoat group, there was a reduction in de novo adhesions at nonsurgical sites by a factor of 2.8. The proportion of sites with de novo adhesions also decreased, and 80% of Sepracoat patients had at least 1 ovary that was adhesion-free compared with 58% of placebo-treated patients. These findings occurred in areas of indirect trauma, demonstrating that Sepracoat limited trauma at tissue injury.

Conclusion

Adhesion prevention is of utmost importance after abdominal myomectomy, especially in patients who desire future fertility. Despite the limited number of prospective, randomized studies, the literature does support the efficacy of various fluid and barrier adjuvants.

Our practice is to use an adjuvant in all abdominal myomectomies. We have long relied on Interceed, which enjoys both ease of application and an excellent safety record. However, as reviewed above, other potentially useful products are available or in development. As ever, the reproductive surgeon should adhere to principles of microsurgery, strive for meticulous hemostasis, and demonstrate respect for tissue integrity.

REFERENCES